In a Bloomberg survey based on the recommendations of 19 brokerage companies, Intuitive Surgical (ISRG) was given “buy” rating by ~68.4% of analysts surveyed. About 26.3% issued “hold” recommendations, and only one firm (5.3% of firms surveyed) issued a “sell” recommendation on the stock.
The table above lists the 12 brokerage firms that provided target prices for Intuitive Surgical for the next 12 months. The consensus 12-month target price is $763.5, which amounts to an ~12% return potential, as compared to Intuitive Surgical’s price of $681.8 on October 20, 2016.
As of October 19, 2016, Northland Securities gave Intuitive Surgical a one-year target price of $600—the lowest target price among analysts—which implies a -12% return over the next 12 months.
Among the large investment banks, Morgan Stanley gave Intuitive Surgical a one-year target price of $800, which implies a ~17.3% return potential over the next 12 months.
Leerink Partners gave the stock its highest one-year target price of $810, which implies a return of ~18.8%.
Peers TransEnterix (TRXC), Medtronic (MDT), and Stryker (SYK) have average broker target prices of $3.3, $94.7, and $127.2, respectively. These figures imply returns of 80.8%, 12.8%, and 11.1%, respectively, during the next 12 months.
Remember, investors can get diversified exposure to Intuitive Surgical by investing in the Vanguard Growth ETF (VUG). VUG has 0.29% of its total holdings in ISRG.